New positive results support early treatment evaluation of breast cancer using DiviTum®
Uppsala, Sweden, 2018-03-28 Results from a study of women with metastatic breast cancer demonstrate that DiviTum can provide faster evaluation of treatment efficacy than today’s standard methods and give precise prognosis.The study, consisting of 31 patients with metastatic breast cancer, was performed at the Prato Hospital, Italy. The results are published in the scientific journal Oncotarget and demonstrates that DiviTum can evaluate efficacy of standard hormonal therapy already after one month of treatment; patients with decreasing DiviTum values did significantly better than patients